Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
- Written by PR Newswire
![]() |
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). In February 2022, golidocitinib received...
Read more: Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL















